MRNA Q2 2026 Earnings — Income Statement Breakdown
For its Q2 2026 period (ending 2026-06-30), MRNA reported revenue of $145M, gross profit of $52M (35.9% gross margin), operating income of −$815M, and net income of −$782M (-539.3% net margin). The flow of revenue into costs and profit is visualized below.
What changed
MRNA reported a net loss; revenue fell 85.7% quarter over quarter.
| Comparison | Revenue | Net income | Net margin |
|---|---|---|---|
| Year over year | Not available | Not available | Not available |
| Quarter over quarter | −85.7% | −291.0% | −519.6 pp |
Consensus estimate data is not available for this report.
MRNA Q2 2026 Income Statement
| Line item | Amount (USD) | % of revenue |
|---|---|---|
| Revenue | $145M | 100% |
| Cost of Revenue | −$93M | 64.1% |
| Gross Profit | $52M | 35.9% |
| Research & Development | −$651M | 449.0% |
| Selling, General & Administrative | −$216M | 149.0% |
| Operating Income | −$815M | -562.1% |
| Other Income, net | $48M | 33.1% |
| Income Tax Expense | −$15M | 10.3% |
| Net Income | −$782M | -539.3% |
Source: MRNA filings on SEC EDGAR (period ended 2026-06-30). Data normalized by EarningsFyi.